No price history available.
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 3,773 | 4,137 | 4,438 | 4,996 | 5,282 | 5,310 | N/A | N/A |
| Operating profit | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | €m | 39 | 91 | 22 | -105 | -55 | 2 | N/A | N/A |
| EPS reported | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Clariane SE, established in Paris, France, in 2001 and known as Korian until its rebranding in June 2023, specializes in delivering comprehensive medical and non-medical care and support. The company serves senior citizens and individuals facing either temporary or chronic health challenges through a diverse range of provisions. These offerings encompass residential facilities like long-term nursing homes, specialized medical clinics, and senior living communities, including assisted living and co-housing arrangements. Furthermore, Clariane extends its services to include in-home care, various support programs, and hospitalization. Its operational footprint spans multiple European nations, including France, Germany, Italy, Spain, the Netherlands, Belgium, and the United Kingdom.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Clariane SE, established in Paris, France, in 2001 and known as Korian until its rebranding in June 2023, specializes in delivering comprehensive medical and non-medical care and support. The company serves senior citizens and individuals facing either temporary or chronic health challenges through a diverse range of provisions. These offerings encompass residential facilities like long-term nursing homes, specialized medical clinics, and senior living communities, including assisted living and co-housing arrangements. Furthermore, Clariane extends its services to include in-home care, various support programs, and hospitalization. Its operational footprint spans multiple European nations, including France, Germany, Italy, Spain, the Netherlands, Belgium, and the United Kingdom.